Presentation is loading. Please wait.

Presentation is loading. Please wait.

Clinical Case HCV therapy following liver transplantation.

Published byRoss Skinner Modified over 9 years ago

Similar presentations

Presentation on theme: "Clinical Case HCV therapy following liver transplantation."— Presentation transcript:

1 Clinical Case HCV therapy following liver transplantation

2 Medical history 65 yrs old HCV (+) LT recipient. HCV-related history: –HCV GT1b –Naïve pre-LT Comorbidities –AHT (nifedipine 60 mg qd) –IDDM (insulin) –Frequent cephalea LT-related history –LT 6 yrs before –MELD 16, Child-Pugh C10 –Anti-core positive donor (recipient HBV serology negative)----LAM prophylaxis –Uneventful surgery & early postLT recovery –IS: Tac + P Recurrent hepatitis C –First month on-demand liver biopsy: mild NI, no fibrosis –6th-month on-demand liver biopsy (ALT 666 UI/ml, AST 373 UI/ml, GGT 280 UI/ml, AP 104 UI/ml) : moderate NI, F2/4

3 Tests performed: –Liver ultrasound: normal –Auto-antibodies: negativos –Thyroid hormones: normal –HBV serology & viral load: negative –CMV viral load: negative –Viral load HCV: >7.692310UI/ml Recurrent hepatitis C Antiviral therapy (9 month postLT) -Peg-alfa-2b 100µg/día -Ribavirin 1000mg/día

4 Time postLTFirst month3d month5th-6th month Biochemical RYesYes (normal) Viral RViral load decreaseYes (84 IU/m)Yes (< 50 IU/ml) AEs* Headache *Anxiety (alprazolam) * Irritability/depression (escitalopram) * Headache * Improvement of depression * Headache * Asthenia *Hand-shaking (D/C nifedipine, propranolol) 3 hospital admissions Laboratory abnormalities * Anemia *Neutropenia *Low platelets * Anemia (EPO) *Neutropenia *Low platelets * Anemia (EPO) *Neutropenia *Low platelets Clinical course during IFN-therapy

5 Third amission (6 months on treatment) Confusion, instability, disorientation, memory loss, urinary incontinence, headache, episodes of unconsciousness with hypertony No fever, no agitation at night, good sleep MRI: normotensive hydrocephaly + Periventricular leucoaraiosis LUMBAR PUNCTURE: Pressure 33 cm H2O, Glu 26 mg/dl, cells 15 (100% MN), proteins: 4,9 g/dl Micro: yeast (criptolatex positive) LOWENSTEIN: Cryptococcus neoformans BURRI Stain: capsulated yests compatible with Cryptococcus ANFOTERICIN B + STOP antiviral therapy

6 -Fibroscan 2011:=6,1 Kpa --Fibroscan 2012 = 15,1 Kpa - Fibrscan 2013: 35 Kpa - Liver biopsy 2014: Cirrhosis with moderate necro-inflammation + macrosteatosis - Gastroscopy: mild esophageal varices Child A 6 Cirrhosis, Meld 14 Baseline viremia: 1.751.000 IU/mL Week 2 viremia: 152 IU/mL Week 4 to 24: undetectable SVR-4 and SVR12 Follow-up Recurrent hepatitis C 24 week- therapy with SOF+DCL+RBV

Download ppt "Clinical Case HCV therapy following liver transplantation."

Similar presentations

Ardis Ann Moe UCLA CARE clinic/NEVHC Van Nuys 21 June 2014

Ardis Ann Moe UCLA CARE clinic/NEVHC Van Nuys 21 June 2014
C.H.B. HCV PRE AND POST-LIVER TRANSPLANTATION Professor Didier SAMUEL Centre Hépatobiliaire, Inserm Unit 785, Paris XI University Hopital Paul Brousse,

C.H.B. HCV PRE AND POST-LIVER TRANSPLANTATION Professor Didier SAMUEL Centre Hépatobiliaire, Inserm Unit 785, Paris XI University Hopital Paul Brousse,
Hepatitis web study Hepatitis web study Sofosbuvir + Ribavirin in HCV Recurrence Following Liver Transplantation Phase 2 Charlton M, et al. Gastroenterology.

Hepatitis web study Hepatitis web study Sofosbuvir + Ribavirin in HCV Recurrence Following Liver Transplantation Phase 2 Charlton M, et al. Gastroenterology.
Hepatitis C What’s New Alan Kilby, M.D. Portland Gastroenterology Center Maine Medical Center VTC Sept 27, 2013.

Hepatitis C What’s New Alan Kilby, M.D. Portland Gastroenterology Center Maine Medical Center VTC Sept 27, 2013.
Management of HCV in Co-Infected Patients Marie-Louise Vachon, MD, MSc Division of Infectious Diseases Centre Hospitalier Universitaire de Québec.

Management of HCV in Co-Infected Patients Marie-Louise Vachon, MD, MSc Division of Infectious Diseases Centre Hospitalier Universitaire de Québec.
Approach to medical liver biopsies Dr Behrang Mozayani Consultant Histopathologist Southmead hospital Bristol.

Approach to medical liver biopsies Dr Behrang Mozayani Consultant Histopathologist Southmead hospital Bristol.
How to optimize the treatment of HCV-4 patients? Nabil Antaki MD, FRCPC Aleppo, Syria Paris, January 30, 2012.

How to optimize the treatment of HCV-4 patients? Nabil Antaki MD, FRCPC Aleppo, Syria Paris, January 30, 2012.
CASE 4 67 yo man HIV+ 1991 Hypertensive CD4 on diagnosis 110/7% AZT initiated soon after diagnosis.

CASE 4 67 yo man HIV Hypertensive CD4 on diagnosis 110/7% AZT initiated soon after diagnosis.
Management of side effects Cirrhotic on telaprevir Vincent LEROY Clinique Universitaire d’Hépato-Gastroentérologie INSERM U823 CHU de Grenoble.

Management of side effects Cirrhotic on telaprevir Vincent LEROY Clinique Universitaire d’Hépato-Gastroentérologie INSERM U823 CHU de Grenoble.
NYU Medical Grand Rounds Clinical Vignette Alexander Jow, PGY-3 February 21, 2012 U NITED S TATES D EPARTMENT OF V ETERANS A FFAIRS.

NYU Medical Grand Rounds Clinical Vignette Alexander Jow, PGY-3 February 21, 2012 U NITED S TATES D EPARTMENT OF V ETERANS A FFAIRS.
Kwo PY. NEJM 2014;371:2375-82 CORAL-I  Design OBV/PTV/r + DSV + RBV Open label Phase II 18-70 years Chronic HCV infection, genotype 1 Liver transplantation.

Kwo PY. NEJM 2014;371: CORAL-I  Design OBV/PTV/r + DSV + RBV Open label Phase II years Chronic HCV infection, genotype 1 Liver transplantation.
1. Sustained suppression of HBV replication Decrease in serum HBV DNA to

1. Sustained suppression of HBV replication Decrease in serum HBV DNA to
Xavier Forns, MD Liver Unit, Hospital Clínic IDIBAPS and CIBREHD Barcelona, Octubre 2013 Tratamiento de poblaciones especiales Curso de Residentes AEEH.

Xavier Forns, MD Liver Unit, Hospital Clínic IDIBAPS and CIBREHD Barcelona, Octubre 2013 Tratamiento de poblaciones especiales Curso de Residentes AEEH.
ATOMIC  Design  Objective –SVR 24 by ITT-analysis, detection of a 30% or 25% difference between two treatment groups, 2-sided significance level of 5%,

ATOMIC  Design  Objective –SVR 24 by ITT-analysis, detection of a 30% or 25% difference between two treatment groups, 2-sided significance level of 5%,
ALLY-1  Design  Objective –SVR 12 (HCV RNA < 25 IU/ml) in genotype 1 DCV 60 mg qd + SOF 400 mg qd + RBV DCV 60 mg qd + SOF 400 mg qd + RBV Not randomised.

ALLY-1  Design  Objective –SVR 12 (HCV RNA < 25 IU/ml) in genotype 1 DCV 60 mg qd + SOF 400 mg qd + RBV DCV 60 mg qd + SOF 400 mg qd + RBV Not randomised.
Alessio Aghemo First Division of Gastroenterology Fondazione IRCCS Ca’ Granda, Ospedale Maggiore Policlinico Università degli Studi di Milano 5 th Paris.

Alessio Aghemo First Division of Gastroenterology Fondazione IRCCS Ca’ Granda, Ospedale Maggiore Policlinico Università degli Studi di Milano 5 th Paris.
ELECTRON  Design SOF + RBV Randomisation* 1 : 1 : 1 : 1 Open-label ELECTRON Study: SOF-based therapy for genotypes 1, 2 and 3 W8W4W12 ≥ 19 years Chronic.

ELECTRON  Design SOF + RBV Randomisation* 1 : 1 : 1 : 1 Open-label ELECTRON Study: SOF-based therapy for genotypes 1, 2 and 3 W8W4W12 ≥ 19 years Chronic.
OBV/PTV/r + DSV + RBV Placebo Randomisation** 3 : 1 Double blind 18-70 years Chronic HCV genotype 1 HCV RNA ≥ 10,000 IU/ml Failure to pre-treatment with.

OBV/PTV/r + DSV + RBV Placebo Randomisation** 3 : 1 Double blind years Chronic HCV genotype 1 HCV RNA ≥ 10,000 IU/ml Failure to pre-treatment with.
OBV/PTV/r + DSV + RBV OBV/PTV/r + DSV Randomisation* 1 : 1 Open label 18-70 years Chronic HCV infection Genotype 1b Prior failure to PEG-IFN + RBV HCV.

OBV/PTV/r + DSV + RBV OBV/PTV/r + DSV Randomisation* 1 : 1 Open label years Chronic HCV infection Genotype 1b Prior failure to PEG-IFN + RBV HCV.
No prior therapy with PI

No prior therapy with PI

Similar presentations

Ads by Google